Novo Nordisk’s Wegovy Gets US Approval for Liver Disease (1)

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the increasingly prevalent condition.

The shot was cleared for the disease known as MASH, or metabolic-associated steatohepatitis, in adults with moderate to advanced scar tissue in the liver. The condition affects about 6% of US adults, or about 14.9 million people, the FDA said in a statement on Friday. The drug is intended to be used in conjunction with a reduced-calorie diet and increased exercise.

The approval ...